vs
Amphastar Pharmaceuticals, Inc.（AMPH）与POWER SOLUTIONS INTERNATIONAL, INC.（PSIX）财务数据对比。点击上方公司名可切换其他公司
POWER SOLUTIONS INTERNATIONAL, INC.的季度营收约是Amphastar Pharmaceuticals, Inc.的1.0倍（$191.2M vs $183.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 8.4%，领先4.9%），POWER SOLUTIONS INTERNATIONAL, INC.同比增速更快（32.5% vs -1.8%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $-7.6M），过去两年POWER SOLUTIONS INTERNATIONAL, INC.的营收复合增速更高（41.7% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
阿达尼能源解决方案有限公司（前身为阿达尼输电有限公司）是一家电力输配企业，总部位于艾哈迈达巴德。截至2025年4月，公司累计输电网络总长26696回路公里，是印度规模最大的民营输电企业之一。
AMPH vs PSIX — 直观对比
营收规模更大
PSIX
是对方的1.0倍
$183.1M
营收增速更快
PSIX
高出34.4%
-1.8%
净利率更高
AMPH
高出4.9%
8.4%
自由现金流更多
AMPH
多$32.2M
$-7.6M
两年增速更快
PSIX
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $191.2M |
| 净利润 | $24.4M | $16.1M |
| 毛利率 | 46.8% | 21.9% |
| 营业利润率 | 19.4% | 12.7% |
| 净利率 | 13.3% | 8.4% |
| 营收同比 | -1.8% | 32.5% |
| 净利润同比 | -35.7% | -31.0% |
| 每股收益（稀释后） | $0.51 | $0.69 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHPSIX
| Q4 25 | $183.1M | $191.2M | ||
| Q3 25 | $191.8M | $203.8M | ||
| Q2 25 | $174.4M | $191.9M | ||
| Q1 25 | $170.5M | $135.4M | ||
| Q4 24 | $186.5M | $144.3M | ||
| Q3 24 | $191.2M | $125.8M | ||
| Q2 24 | $182.4M | $110.6M | ||
| Q1 24 | $171.8M | $95.2M |
净利润AMPHPSIX
| Q4 25 | $24.4M | $16.1M | ||
| Q3 25 | $17.4M | $27.6M | ||
| Q2 25 | $31.0M | $51.2M | ||
| Q1 25 | $25.3M | $19.1M | ||
| Q4 24 | $38.0M | $23.3M | ||
| Q3 24 | $40.4M | $17.3M | ||
| Q2 24 | $37.9M | $21.5M | ||
| Q1 24 | $43.2M | $7.1M |
毛利率AMPHPSIX
| Q4 25 | 46.8% | 21.9% | ||
| Q3 25 | 51.4% | 23.9% | ||
| Q2 25 | 49.6% | 28.2% | ||
| Q1 25 | 50.0% | 29.7% | ||
| Q4 24 | 46.5% | 29.9% | ||
| Q3 24 | 53.3% | 28.9% | ||
| Q2 24 | 52.2% | 31.8% | ||
| Q1 24 | 52.4% | 27.0% |
营业利润率AMPHPSIX
| Q4 25 | 19.4% | 12.7% | ||
| Q3 25 | 13.2% | 13.9% | ||
| Q2 25 | 24.2% | 16.9% | ||
| Q1 25 | 21.9% | 18.2% | ||
| Q4 24 | 24.2% | 17.5% | ||
| Q3 24 | 29.8% | 16.3% | ||
| Q2 24 | 30.3% | 22.9% | ||
| Q1 24 | 27.9% | 11.2% |
净利率AMPHPSIX
| Q4 25 | 13.3% | 8.4% | ||
| Q3 25 | 9.0% | 13.5% | ||
| Q2 25 | 17.8% | 26.7% | ||
| Q1 25 | 14.8% | 14.1% | ||
| Q4 24 | 20.4% | 16.1% | ||
| Q3 24 | 21.1% | 13.8% | ||
| Q2 24 | 20.8% | 19.5% | ||
| Q1 24 | 25.1% | 7.5% |
每股收益（稀释后）AMPHPSIX
| Q4 25 | $0.51 | $0.69 | ||
| Q3 25 | $0.37 | $1.20 | ||
| Q2 25 | $0.64 | $2.22 | ||
| Q1 25 | $0.51 | $0.83 | ||
| Q4 24 | $0.74 | $1.01 | ||
| Q3 24 | $0.78 | $0.75 | ||
| Q2 24 | $0.73 | $0.94 | ||
| Q1 24 | $0.81 | $0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $41.3M |
| 总债务越低越好 | $608.7M | $96.6M |
| 股东权益账面价值 | $788.8M | $178.6M |
| 总资产 | $1.6B | $424.7M |
| 负债/权益比越低杠杆越低 | 0.77× | 0.54× |
8季度趋势，按日历期对齐
现金及短期投资AMPHPSIX
| Q4 25 | $282.8M | $41.3M | ||
| Q3 25 | $276.2M | $49.0M | ||
| Q2 25 | $231.8M | $49.5M | ||
| Q1 25 | $236.9M | $50.0M | ||
| Q4 24 | $221.6M | $55.3M | ||
| Q3 24 | $250.5M | $40.5M | ||
| Q2 24 | $217.8M | $28.8M | ||
| Q1 24 | $289.6M | $33.1M |
总债务AMPHPSIX
| Q4 25 | $608.7M | $96.6M | ||
| Q3 25 | $608.6M | $96.7M | ||
| Q2 25 | $607.7M | $1.8M | ||
| Q1 25 | $603.9M | $1.0M | ||
| Q4 24 | $601.6M | $184.0K | ||
| Q3 24 | $596.4M | $238.0K | ||
| Q2 24 | $586.9M | $292.0K | ||
| Q1 24 | $594.0M | $345.0K |
股东权益AMPHPSIX
| Q4 25 | $788.8M | $178.6M | ||
| Q3 25 | $776.7M | $162.5M | ||
| Q2 25 | $757.5M | $135.7M | ||
| Q1 25 | $751.3M | $84.3M | ||
| Q4 24 | $732.3M | $65.3M | ||
| Q3 24 | $727.7M | $42.1M | ||
| Q2 24 | $713.3M | $24.8M | ||
| Q1 24 | $672.4M | $3.2M |
总资产AMPHPSIX
| Q4 25 | $1.6B | $424.7M | ||
| Q3 25 | $1.7B | $458.9M | ||
| Q2 25 | $1.6B | $437.7M | ||
| Q1 25 | $1.6B | $372.7M | ||
| Q4 24 | $1.6B | $328.2M | ||
| Q3 24 | $1.5B | $339.1M | ||
| Q2 24 | $1.5B | $307.6M | ||
| Q1 24 | $1.6B | $286.8M |
负债/权益比AMPHPSIX
| Q4 25 | 0.77× | 0.54× | ||
| Q3 25 | 0.78× | 0.60× | ||
| Q2 25 | 0.80× | 0.01× | ||
| Q1 25 | 0.80× | 0.01× | ||
| Q4 24 | 0.82× | 0.00× | ||
| Q3 24 | 0.82× | 0.01× | ||
| Q2 24 | 0.82× | 0.01× | ||
| Q1 24 | 0.88× | 0.11× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $-4.6M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $-7.6M |
| 自由现金流率自由现金流/营收 | 13.4% | -4.0% |
| 资本支出强度资本支出/营收 | 4.5% | 1.6% |
| 现金转化率经营现金流/净利润 | 1.35× | -0.29× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $14.1M |
8季度趋势，按日历期对齐
经营现金流AMPHPSIX
| Q4 25 | $32.9M | $-4.6M | ||
| Q3 25 | $52.6M | $3.3M | ||
| Q2 25 | $35.6M | $16.7M | ||
| Q1 25 | $35.1M | $8.8M | ||
| Q4 24 | $29.0M | $32.7M | ||
| Q3 24 | $60.0M | $12.6M | ||
| Q2 24 | $69.1M | $1.5M | ||
| Q1 24 | $55.3M | $15.6M |
自由现金流AMPHPSIX
| Q4 25 | $24.6M | $-7.6M | ||
| Q3 25 | $47.2M | $1.7M | ||
| Q2 25 | $25.0M | $14.6M | ||
| Q1 25 | $24.4M | $5.4M | ||
| Q4 24 | $16.6M | $30.0M | ||
| Q3 24 | $46.2M | $12.1M | ||
| Q2 24 | $63.1M | $822.0K | ||
| Q1 24 | $46.5M | $14.8M |
自由现金流率AMPHPSIX
| Q4 25 | 13.4% | -4.0% | ||
| Q3 25 | 24.6% | 0.8% | ||
| Q2 25 | 14.3% | 7.6% | ||
| Q1 25 | 14.3% | 4.0% | ||
| Q4 24 | 8.9% | 20.8% | ||
| Q3 24 | 24.1% | 9.7% | ||
| Q2 24 | 34.6% | 0.7% | ||
| Q1 24 | 27.1% | 15.6% |
资本支出强度AMPHPSIX
| Q4 25 | 4.5% | 1.6% | ||
| Q3 25 | 2.8% | 0.8% | ||
| Q2 25 | 6.1% | 1.1% | ||
| Q1 25 | 6.3% | 2.5% | ||
| Q4 24 | 6.7% | 1.8% | ||
| Q3 24 | 7.2% | 0.3% | ||
| Q2 24 | 3.3% | 0.6% | ||
| Q1 24 | 5.1% | 0.9% |
现金转化率AMPHPSIX
| Q4 25 | 1.35× | -0.29× | ||
| Q3 25 | 3.03× | 0.12× | ||
| Q2 25 | 1.15× | 0.33× | ||
| Q1 25 | 1.39× | 0.46× | ||
| Q4 24 | 0.76× | 1.40× | ||
| Q3 24 | 1.48× | 0.73× | ||
| Q2 24 | 1.82× | 0.07× | ||
| Q1 24 | 1.28× | 2.20× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PSIX
| Energy End Market | $153.4M | 80% |
| Industrial End Market | $33.3M | 17% |
| Transportation End Market | $4.6M | 2% |
